Phase 2 Study of TD-9855 to Treat Fibromyalgia

NCT01693692 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

392

Enrollment

INDUSTRY

Sponsor class

Conditions

Fibromyalgia

Interventions

DRUG: TD-9855 Group 1
DRUG: TD-9855 Group 2
DRUG: Placebo

Sponsor

Theravance Biopharma